/term/price-to-ffo/FRA:2B30 Xeris Biopharma Holdings (FRA:2B30) Price-to-Funds-From-Ope
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (FRA:2B30) » Definitions » Price-to-Funds-From-Operations

Xeris Biopharma Holdings (FRA:2B30) Price-to-Funds-From-Operations : (As of Jun. 20, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.

Xeris Biopharma Holdings (FRA:2B30) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (FRA:2B30) » Definitions » Price-to-Funds-From-Operations
Comparable Companies
YMAB DRTS CMPX CELC ACIU IGMS NUVB ARQT ZURA OVID OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
XERS:USA 0A8E:UK
Address
180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601
Website
https://www.xerispharma.com
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.